Table 6:
Top 5 Canonical Pathways from Ingenuity Pathway Analysis (IPA).
| Omics Data | Top Canonical Pathway | P-value | Molecules Selected |
|---|---|---|---|
| RNA Sequencing | 4-hydroxybensoate Biosynthesis | 2.07E-03 | TAT |
| 4-hydroxyphneylpyruvate Biosythesis | 2.07E-03 | TAT | |
| Tyrosine Degradation 1 | 1.03E-02 | TAT | |
| Role of IL-17A in Psoriasis | 2.86E-02 | CCL20 | |
| Fatty Acid Activation | 2.86E-02 | ACSM1 | |
| Proteomics | LXR/RXR Activation | 4.14E-11 | AGT, ALB, APOA2, APOH, APOM, CLU, PON1, TF |
| FXR/RXR Activation | 5.02E-11 | AGT, ALB, APOA2, APOH, APOM, CLU, PON1, TF | |
| Acute Phase Response Signaling | 3.30E-08 | AGT, ALB, APOA2, APOH, HRG, SERPINA3, TF | |
| Atherosclerosis Signaling | 1.06E-07 | ALB, APOA2, APOM, CLU, COL18A1, PON1 | |
| Clathrin-mediated Endocytosis Signaling | 1.09E-06 | ALB, APOA2, APOM, CLU, PON1, TF | |
| Metabolomics | tRNA Charging | 2.25E-13 | L-glutamic acid, L-Phenylalanine, L-Glutamine, Glycine, L-Serine, L-Methionine; L-Valine, L-Isoleucine, L-Threonine, L-Tryptophan, L-Proline |
| Glutamate Receptor Signaling | 5.43E-05 | L-glutamic acid, glycine, L-Glutamine | |
| Phenylalanine Degradation IV (Mammalian, via Side Chain) | 7.24E-05 | L-glutamic acid, glycine, L-Glutamine, L-Phenylalanine | |
| Superpathway of Serine and Clycine Biosynthesis I | 3.28E-04 | L-glutamic acid, glycine, L-serine | |
| y-glutamyl Cycle | 4.23E-04 | L-glutamic acid, glycine, pyrrolidonecarboxylic acid |